Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cogent Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
COGT
Nasdaq
2834
https://www.cogentbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cogent Biosciences Inc
COGT Reports Full Year 2023 Financial Results and Business Highlights
- Feb 28th, 2024 9:32 am
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Feb 26th, 2024 1:00 pm
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
- Feb 22nd, 2024 7:30 pm
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
- Feb 14th, 2024 12:00 pm
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
- Feb 5th, 2024 2:00 pm
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
- Jan 9th, 2024 1:00 pm
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 1:00 pm
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- Dec 11th, 2023 12:55 pm
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
- Dec 9th, 2023 6:30 pm
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
- Dec 7th, 2023 2:00 pm
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
- Dec 4th, 2023 1:00 pm
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
- Nov 29th, 2023 1:00 pm
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans?
- Nov 27th, 2023 5:01 pm
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
- Nov 2nd, 2023 1:00 pm
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 14th, 2023 4:30 pm
After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain
- Aug 13th, 2023 12:51 pm
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
- Aug 8th, 2023 12:00 pm
Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023
- Jul 10th, 2023 11:35 pm
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
- Jun 9th, 2023 8:01 pm
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
- Jun 7th, 2023 1:00 pm
Scroll